Expanding Medicare coverage for glucagon-like peptide 1 (GLP-1) receptor agonists could significantly reduce obesity-related ...

The rising use of GLP-1 agonists to help manage the obesity epidemic is not only reshaping how consumers taking the ...

Experts express alarm that GLP-1 RAs may trigger or worsen eating disorders. But is there any role they might play in binge ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep medicine.

Topline data were announced from a phase 3 trial evaluating orforglipron in adults with T2D and inadequate glycemic control with diet and exercise alone.

Both GLP-1 RAs and SGLT2is are associated with a reduced risk for Alzheimer disease and related dementias among people with type 2 diabetes.

A new study from Rutgers University links higher body dissatisfaction, BMI, and maladaptive weight loss behaviors with ...

As a large proportion of people taking medications like Mounjaro, Ozempic and Wegovy for weight loss report consuming less processed foods and soda, researchers say food and beverage companies are ...

Discover how Viking Therapeutics, Inc.'s VK2735 and VK2809 target obesity and NASH markets. Click for my updated look at VKTX ...

New research highlights how GLP-1 receptor agonists influence gut bacteria, offering insights into their broader metabolic and anti-inflammatory benefits. Study: Effects of GLP-1 Analogues and ...

The annual prevalence increased to 0.4% by 2022, with an estimated 854,728 adults without diabetes using GLP-1 RAs. HealthDay News — Among US adults without diabetes, the use of glucagon-like ...

THURSDAY, April 10, 2025 (HealthDay News) -- Among U.S. adults without diabetes, the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) increased from 2018 to 2022, reaching annual ...